KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer
The KRAS G12C inhibitor adagrasib on its own shrank about one in five previously treated colorectal cancers, but combined with the EGFR antibody cetuximab the response rate rose to nearly half, showing the two drugs are needed together in this disease.
Overview
Phase 1/2 study including 44 patients with KRAS G12C-mutated metastatic colorectal cancer treated with adagrasib alone and 32 treated with adagrasib plus cetuximab, all heavily pretreated.
Objective response was 19 percent with monotherapy (median progression-free survival 5.6 months) and 46 percent with the combination (median progression-free survival 6.9 months, median overall survival 13.4 months).
- Objective response 19 percent with adagrasib alone vs 46 percent with adagrasib plus cetuximab.
- Median overall survival 13.4 months with the combination.
Adagrasib plus cetuximab is an approved option for previously treated KRAS G12C colorectal cancer, alongside sotorasib plus panitumumab; monotherapy is not enough because EGFR signalling reactivates the pathway.
- Small single-arm cohorts.
- Responses are shorter than in KRAS G12C lung cancer.
Similar pages
not linked directly; found by shared links- TrialPhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
- Key paperSUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
Shares KRAS G12C-mutant colorectal cancer, New England Journal of Medicine.
- TrialJAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
- Key paperEXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer
Shares Cetuximab, New England Journal of Medicine.
- TrialPhase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
- TrialA Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- Key paperRadiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck
Shares Cetuximab, New England Journal of Medicine.
- TrialA Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation